

Elpiscience to Showcase Three Innovative Research Studies

at the SITC 2025 Annual Meeting

Elpiscience Biopharmaceuticals today announced that it will showcase three cutting-edge research studies through poster presentations at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025), taking place November 5–9, 2025, in National Harbor, Maryland, USA. The posters involve the company's internally developed Bispecific Macrophage Engager (BiME®), the LILRB2-targeting monoclonal antibody ES009, and the bispecific NK cell engager (NKCE) ES038.

The SITC Annual Meeting is the world's largest international conference dedicated to cancer immunotherapy. As one of the most influential and professional academic conferences globally, it gathers thousands of industry leaders and representatives from academia, regulatory agencies, and government institutions worldwide each year to exchange cutting-edge results and discuss future directions. The 2024 SITC meeting attracted more than 6,000 participants worldwide.

Elpiscience has been selected to participate in SITC Annual Meeting for five consecutive years, highlighting the company's independent innovation capabilities and significant progress in tumor immunology research. This year, the BiME® study was recognized among the "Top 150 Abstracts" from thousands of selected global submissions, further validating the international academic recognition of BiME®'s originality and promising potential in solid tumor treatment.

Details of Elpiscience's posters at SITC 2025 are as follows:

Poster 1

Title: Novel Bispecific Macrophage Engager (BiME) Antibodies Activate T Cells and Induce Durable Immune Memory to Suppress Tumor Growth

Abstract No.: 1168

Session Date: November 8, 2025

Poster 2

Title: A First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the LILRB2 Inhibitor ES009 in Patients with Advanced Solid Tumors

Abstract No.: 596

Session Date: November 8, 2025

Poster 3



Title: ES038, a Novel NKCE Molecule Targeting LILRB4 in AML via Dual Engagement of NKG2A and NKG2C

Abstract No.: 435

Session Date: November 7, 2025

For more information about the meeting and posters, please visit the SITC official website: <https://www.sitcancer.org/2025/home>

###

About Elpiscience

Elpiscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. By advancing breakthrough biologics and leveraging global strategic partnerships, Elpiscience has built a differentiated pipeline to deliver transformative treatment solutions for patients worldwide.

BD inquiries:

BD@elpiscience.com

Media inquiries:

PR@elpiscience.com